Usefulness of Serum Brain Natriuretic Peptide as a Predictor Biomarker of Renal Artery Stenosis in Patients with Resistant Hypertension

Sevil UYGUN İLİKHAN, Muammer BİLİCİ

Bulent Ecevit University, Faculty of Medicine, Department of Internal Medicine, Zonguldak, Turkey

Cite this article as: Yüksel S, Bilici M. Usefulness of Serum Brain Natriuretic Peptide as a Predictor Biomarker of Renal Artery Stenosis in Patients with Resistant Hypertension. Türk Diyabet Obez 2019;3: 155-163.

ABSTRACT

Aim: In this study, we aimed to evaluate the relationship between BNP level and RAS in patients with resistant hypertension according to the results of renal arteriography.

Material and Methods: Forty patients with resistant hypertension were included to the study. In order to compare to each other regarding the BNP levels, the patients were evaluated by dividing them into groups as RAS (group 1; non-critical (1a) and critical (1b)), non-RAS (group 2), unilateral RAS (non-critical (A) and critical (B)) and bilateral RAS (non-critical (C) and critical (D)) according to the results of renal arteriography.

Results: The serum BNP (p=0.003) and serum creatinine (p=0.015) levels of group 1b were also significantly higher than group 1a. The patients in group B had higher serum BNP levels (p=0.025) and lower creatinine clearance levels (p=0.041) compared to group A. Higher serum creatinine (p=0.006), serum BNP levels (p=0.017) and lower creatinine clearance levels (p=0.049) have been observed in group D compared to group C.

Conclusion: Findings of this study revealed that increased serum BNP levels were significantly associated with the severity of RAS determined by the results of renal arteriography. Thus BNP may be used as a predictive marker to detect the presence of RAS in patients with resistant hypertension.

Key Words: Brain natriuretic peptide, Renal artery stenosis, Resistant hypertension

ÖZET

Amaç: Bu çalışmada dirençli hipertansiyon ön tanısyyla selektif renal arteriografisi yapılan ve renal arter stenozu (RAS) saptanan hastalarda serum beyin natriüretik peptit (BNP) düzeyleri ile RAS arasındaki ilişkini değerlendirilmesi amaçlandı.

Gereç ve Yöntemler: Dirençli hipertansiyonu olan 40 hasta çalışmaya alınmıştır. Hastalar renal arter arteriografisi sonucuna göre RAS olan (Grup 1) ve olmayan (Grup 2) olmak üzere iki gruba ayrıldı. Renal arterde darlığı % 50den az olanları Grup 1, diğerleri Grup 1b olarak kabul edildi. Unilateral non-kritik RAS tespit edilen hastalar Grup A, unilateral kritik RAS tespit edilenler Grup B, bilateral non-kritik RAS tespit edilenler Grup C ve bilateral kritik RAS tespit edilen grupları Grup D olarak kabul edildi. Hasta grupları BNP düzeyleri açısından karşılaştırıldı.

Bulgular: Grup 1b hastalarda serum BNP ve serum kreatinin değerleri Grup 1a'ya göre daha yüksek saptandı (srasıyla, p=0.003 ve p=0.015). Grup B hastaları A grubundakilere göre daha yüksek serum BNP düzeyleri ve daha düşük kreatinin klerensine sahiptiler (srasıyla, p=0.025 ve p=0.041). Ayrıca D grubu hastaların kritik RAS tespit edildiğinde yüksek serum BNP, kreatinin düzeyleri ve daha düşük kreatinin klerensine sahiptiler(srasıyla, p=0.017, p=0.006 ve p=0.049).

ORCID: Sevil Uygun İlikhan / 0000-0002-0162-5729, Muammer Bilici / 0000-0002-8678-4605

DOI: 10.25048/tjdo.2019.55

Received / Geliş tarihi: 04.12.2019
Revision / Revizyon tarihi: 17.12.2019
Accepted / Kabul tarihi: 26.12.2019
INTERVENTION

Renovascular disease (RVD) is a major cause of secondary hypertension that may cause progressive loss of kidney functions and end-stage renal failure (1,2). Renal artery stenosis (RAS) is usually caused by atherosclerosis or fibromuscular dysplasia and also renovascular hypertension is the most common curable cause of high blood pressure (3). Significant renal artery stenosis leads to activation of the renin-angiotensin-aldosterone system and may initiate or exacerbate hypertension, ischemic nephropathy, left ventricular hypertrophy and congestive heart failure (4). The clinical index of suspicion remains paramount in setting the diagnostic strategy (1). There are a number of available tests that can be used to detect RAS including Doppler ultrasound, magnetic resonance angiography (MRA), computed tomography angiography (CTA), renal scintigraphy (i.e. captopril scan), peripheral renin levels, renal vein renin sampling, and selective renal arteriography. Although conventional selective renal arteriography is usually considered the gold standard in confirming the diagnosis of RAS, these tests are based on identifying the functional consequences and the presence of anatomic stenosis of RVD (5).

Brain natriuretic peptide (BNP) is a neurohormone that belongs to the family of natriuretic peptides (6). BNP is synthesized and released mainly from the cardiomyocytes, under genomic control, in response to ventricular wall stretch (7). Elevated levels of BNP which has an approximately 20 minutes of serum half-life, have been shown in chronic renal failure undergoing haemodialysis (8).

The most important physiological effects of BNP are diuresis, natriuresis and arterial vasodilation. These effects depend on inhibition of renin that causes reducing the activity of the renin-angiotensin system. Furthermore, in vitro data have also revealed that angiotensin II directly induces the synthesis and release of BNP. The increased angiotensin II because of the renin-angiotensin-aldosterone system activated via significant RAS, may contribute to increase plasma BNP level (9-11). Experimental studies suggest that the critical stenosis of renal artery more than 70-80% causes renal parenchymal damage and hypertension. Although the critical ratio of renal artery stenosis is yet unknown, the lesion stenosis over 50% of renal artery is recommended as a significant lesion for humans (12).

Nowadays, the plasma BNP level has been used as a biological marker in the diagnosis and treatment of some diseases, especially cardiovascular events (13). Measurement of BNP enable the diagnosis and treatment of these diseases, and also it may allow to reduce the total cost of management approaches (6,14). Recently, rapid BNP assay is now easily available to physicians in an office, clinic and emergency department.

The aim of this study is to investigate whether plasma levels of BNPs may predict the presence of RAS in patients with resistant hypertension.

MATERIALS and METHODS

Patient Population

Seventy-two patients with resistant hypertension and preliminary diagnosis of RAS according to doppler ultrasound results were included to the present study. Resistant hypertension was defined as blood pressure of 140/90 mm Hg or higher despite the usage of 3 or more medications including one diuretic (15). Thirty-two patients were executed from study according to execution criterias. Selective renal artery angiography was performed to 40 patients (Female/Male: 28/22, mean age: 51.1 ± 5.6). Physical examination, routine laboratory tests and examinations in terms of end organ damage (echocardiography, 24-hour urine analysis and fundus examination) were performed to all patients.

Patients with resistant hypertension were divided into two groups as RAS (Group 1, n=30) and non-RAS (Group 2, n=10 (that no renal artery stenosis could be detected)) according to the results of selective renal artery angiography. Group 2 was determined as control group. Patients with RAS (Group 1) were also divided into two groups, as Group 1a and Group 1b, according to the degree of stenosis determined by selective renal artery angiography. Group 1a (n=13) and Group 1b (n=17) were determined as patients with renal artery stenosis less than 50% (non-critical) and more than 50% (critical), respectively (12). In addition, patients with RAS were divided into two groups as the unilateral RAS group and the bilateral RAS group. These groups were also divided into two groups as critical and non-critical. Patients with non-critical unilateral RAS were considered as Group A (n=7), and patients with critical unilateral RAS
were considered as Group B (n=12). Patients with non-critical bilateral RAS were considered as Group C (n=6), while patients with critical bilateral RAS were considered as Group D (n=5). General characteristics of the study group are presented in Table 1.

The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by our institution’s human research committee (the clinical trial registration number: 05.06.2008/08). Informed consent was obtained from all individuals.

**Biochemical Analysis**

The patients’ blood samples were taken between 08:00 - 10:00 a.m. after 8 hours of fasting. Urinary creatinine levels were evaluated by Moduler P device (Roche, Tokyo, Japan) using commercial kits of Roche Company. Venous blood samples for BNP were taken into tubes with EDTA and were analyzed in Beckman Coulter Access 2 (Fullerton, CA, USA) device by chemiluminescence method. Creatinine Clearance (ml/min) was calculated by the formula as follows: Creatinine Clearance (ml/minute) = urine creatinine (mg / dl) x daily urine volume (ml) / serum creatinine (mg / dl) x 1440.

**Selective Renal Artery Angiography**

Renal angiography was performed with Philips Integris H 5000 cineangiography device. The degree and location of stenosis were calculated by a computer program of the Philips Workstation software. The degree of stenosis of > 50% was considered as the presence of hemodynamically significant stenosis (12).

**Exclusion Criteria**

Patients with acute coronary syndrome and pulmonary embolism history within the last six months, chronic renal failure, heart failure symptoms and / or ejection fraction (EF) <45%, hemodynamically significant heart valve disease, previously known diabetes mellitus, pregnancy, hypothyroidism, hyperthyroidism, tuberculosis or tuberculosis treatment history, 24-hour urine sodium level more than 100 mEq in terms of monitoring daily sodium intake and history of β-blockers, angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) usage as antihypertensive drugs were excluded from the study. Echocardiographic evaluations were performed by using General Electric Vingmed Vivid FIVE echocardiography device.

**Statistical Analysis**

SPSS 19.0 for Windows used for statistical analysis. Categorical variables are given with frequency and percent, while numerical variables are given with mean and standard deviation values. For data analysis, Mann-Whitney U-test and chi-square test were used. Also compliance with

**Table 1: Demographics and clinical variables of groups.**

| Characteristic            | Patients (Group1)(n=30) Mean ± Sd | Controls (Group2)(n=10) Mean ± Sd | P     |
|--------------------------|-----------------------------------|-----------------------------------|-------|
| Age                      | 51.5 ± 5.6                        | 50.1 ± 5.9                        | 0.338 |
| Gender (male/female)     | 14/16                             | 3/7                               | 0.324 |
| Systolic blood pressure (mmHg) | 179.3 ± 12.1                     | 158 ± 6.3                         | < 0.001 |
| Diastolic blood pressure (mmHg) | 104 ± 8.7                      | 95 ± 9.7                          | 0.013 |
| Urea (mg/dl)             | 36.6 ± 9.3                        | 41.1 ± 6.8                        | 0.094 |
| Creatinine (mg/dl)       | 0.85 ± 0.2                        | 0.78 ± 0.1                        | 0.365 |
| Potassium (mEq/L)        | 4.3 ± 0.3                         | 4.4 ± 0.3                         | 0.286 |
| Sodium (mEq/L)           | 141.5 ± 3.4                       | 143.6 ± 2.9                       | 0.104 |
| Serum BNP (mg/dl)        | 80.5 ± 30.3                       | 47.2 ± 10.5                       | < 0.001 |
| Microalbuminuria (mg/24h) | 38.8 ± 47.1                      | 8.8 ± 4.4                         | 0.033 |
| Microproteinuria (mg/24h) | 215.9 ± 178.0                   | 173.9 ± 110.5                     | 0.901 |
| Creatinine clearance (ml/min) | 92.4 ± 17.5                | 94.5 ± 11.6                       | 0.272 |
| EF %                     | 59.7 ± 5.5                        | 60.3 ± 1.8                        | 0.924 |
| LVMI (g/m²)              | 165.8 ± 29.7                      | 152.4 ± 10.9                      | 0.174 |
| BMI (kg/ m²)             | 25.7 ± 1.2                        | 25.4 ± 1.3                        | 0.509 |

**BNP**: Brain natriuretic peptide, **EF**: Ejection Fraction, **Sd**: Standard deviation, **LVMI**: Left ventricular mass index, **BMI**: Body mass index
normal distribution was evaluated by Shapiro-Wilk test. For all statistical analysis, p value under 0.05 is assumed as there is a statistical significance.

RESULTS

Patients with resistant hypertension were divided into two groups as with RAS (Group 1, n=30) and non-RAS (Group 2, n=10) according to renal arteriography results. Group 2 was determined as the control group. Patients with RAS (Group 1) were also divided into two groups, as group 1a (n=13) and group 1b (n=17), according to the degree of stenosis determined by renal arteriography (renal artery stenosis less than 50% and more than 50%, respectively). Demographic and clinical characteristics of patients with RAS and non-RAS control group are presented in Table 1. The systolic (p<0.001) and diastolic (p=0.013) blood pressure, serum BNP (p<0.001), microalbuminuria (p=0.033) levels of group 1 were significantly higher than group 2. There was no statistically significant difference in terms of age and gender (p>0.05) between control group 1 and 2. It was also observed that the serum BNP (p=0.003) and serum creatinine (p=0.015) levels of Group 1b were significantly higher than Group 1a; however, the creatinine clearance levels were significantly lower compared to group 1a (p=0.007). The blood pressure measurements were similar in these groups. There were no statistically significant differences between Group 1a and 1b in terms of age and gender distribution (p=0.388, p=0.133, respectively) (Table 2).

Patients with RAS were divided into two groups as unilateral and bilateral stenosis. These groups were also divided into two groups as critical and non-critical. Patients with unilateral non-critical and critical RAS were considered as Group A (n=7) and Group B (n=12) respectively. Patients with bilateral non-critical and critical RAS were considered as Group C (n=6) and Group D (n=5) respectively. The patients in group B had higher serum BNP levels (p=0.025) and lower creatinine clearance levels (p=0.041) compared to group A. Higher serum creatinine (p=0.006) and serum BNP levels (p=0.017) as well as lower creatinine clearance levels (p=0.049) have been detected in group D when compared to Group C (Table 3).

The ocular fundus findings occurred due to resistant hypertension in patients with RAS and non-RAS were detected. There were significant differences between patients with grade 1 and grade 2 hypertensive retinopathy (HR) in terms of systolic (p=0.003) and diastolic (p=0.049) blood pressure, serum creatinine (p=0.008), serum BNP (p=0.009), microalbuminuria (p=0.013) and microproteinuria (p=0.027) levels; however, the creatinine clearance (p=0.057) levels were statistically lower in patients with grade 1 HR than with grade 2 HR (Table 4).

| Characteristic                  | Group 1a (Non-critical RAS) n=13 Mean ± Sd | Group 1b (Critical RAS) n=17 Mean ± Sd | P |
|--------------------------------|------------------------------------------|--------------------------------------|---|
| Age                           | 50.3 ± 5.5                               | 52.4 ± 5.7                           | 0.388 |
| Gender (male/female)          | 4/9                                      | 10/7                                 | 0.133 |
| Systolic blood pressure (mmHg) | 179.2 ± 14.4                             | 179.4 ± 10.4                         | 0.863 |
| Diastolic blood pressure (mmHg)| 103.1 ± 9.5                              | 105.0 ± 8.2                          | 0.667 |
| Urea (mg/dl)                  | 34.5 ± 9.2                               | 38.2 ± 9.4                           | 0.357 |
| Creatinine (mg/dl)            | 0.75 ± 0.1                               | 0.9 ± 0.2                            | 0.015 |
| Potassium (mEq/L)             | 4.3 ± 0.3                                | 4.4 ± 0.4                            | 0.900 |
| Sodium (mEq/L)                | 141.5 ± 3.5                              | 141.6 ± 3.5                          | 0.782 |
| Serum BNP (mg/dl)             | 63.1 ± 14.1                              | 93.8 ± 32.8                          | 0.003 |
| Microalbuminuria (mg/24h)     | 51.8 ± 64.1                              | 28.8 ± 26.2                          | 0.753 |
| Microproteinuria (mg/24h)     | 269.9 ± 221.7                            | 174.5 ± 128.7                        | 0.286 |
| Creatinine clearance (ml/min) | 102.8 ± 18.9                             | 84.4 ± 11.5                          | 0.007 |
| EF %                          | 59.3 ± 4.9                               | 60.4 ± 6.0                           | 0.537 |
| LVMI (g/m²)                   | 165.8 ± 29.2                             | 165.8 ± 30.9                         | 0.983 |
| BMI (kg/m²)                   | 25.7 ± 0.8                               | 25.7 ± 1.4                           | 0.770 |

BNP: Brain natriuretic peptid, EF: Ejection Fraction, Sd: Standard deviation, LVMI: Left ventricular mass index, BMI: Body mass index.

Table 2: The comparison of groups among patients with RAS according to severity of RAS.
Table 3: The comparison of groups with non-critical and critical stenosis in patients with unilateral or bilateral RAS.

| Variables                      | Unilateral RAS |          |          |          | Bilateral RAS |          |          |          |
|--------------------------------|----------------|----------|----------|----------|---------------|----------|----------|----------|
|                                | Noncritical    | Critical |          |          | Noncritical   | Critical |          |          |
|                                | (A) (n=7) Mean ± Sd |         | (B) (n=12) Mean ± Sd |          |               | (C) (n=6) Mean ± Sd | (D) (n=5) Mean ± Sd |          |
| Age                            | 48.6 ± 6.7      | 54.0 ± 5.9 |          | 0.108    | 52.2 ± 3.2    | 48.6 ± 2.8 |          | 0.085    |
| Gender (male/female)           | 2/5             | 7/5      |          | 0.223    | 2/4           | 3/2      |          | 0.399    |
| Systolic blood pressure (mmHg) | 171.4 ± 14.6    | 176.7 ± 10.9 |          | 0.409    | 188.3 ± 7.5   | 186.0 ± 5.5 |          | 0.609    |
| Diastolic blood pressure (mmHg)| 98.5 ± 10.6     | 103.7 ± 9.3 |          | 0.271    | 108.3 ± 4.0   | 108.0 ± 4.5 |          | 0.892    |
| Urea (mg/dl)                   | 31.8 ± 10.4     | 39.3 ± 10.5 |          | 0.150    | 37.5 ± 7.3    | 34.8 ± 5.3 |          | 0.714    |
| Creatinine (mg/dl)             | 0.7 ± 0.07      | 0.8 ± 0.2 |          | 0.226    | 0.8 ± 0.1     | 1.1 ± 0.1 |          | 0.006    |
| Potassium (mEq/L)              | 4.4 ± 0.3       | 4.3 ± 0.3 |          | 0.467    | 4.3 ± 0.4     | 4.6 ± 0.4 |          | 0.463    |
| Sodium (mEq/L)                 | 140.6 ± 3.1     | 141.6 ± 3.4 |          | 0.385    | 142.5 ± 3.9   | 141.8 ± 4.4 |          | 0.854    |
| Serum BNP (mg/dl)              | 58.3 ± 12.6     | 94.7 ± 39.2 |          | 0.025    | 68.6 ± 14.8   | 92.0 ± 9.7 |          | 0.017    |
| Microalbuminuria (mg/24h)      | 29.4 ± 32.4     | 26.8 ± 27.1 |          | 0.999    | 78.0 ± 84.2   | 33.6 ± 26.1 |          | 0.647    |
| Microproteinuria (mg/24h)      | 174.3 ± 156.9   | 184.7 ± 149.9 |          | 0.899    | 381.5 ± 245.1 | 150.2 ± 57.6 |          | 0.201    |
| Creatinine clearance (ml/min)  | 106.7 ± 23.2    | 85.9 ± 12.4 |          | 0.041    | 98.1 ± 13.1   | 80.8 ± 9.1 |          | 0.049    |
| EF %                           | 61.3 ± 4.3      | 59.7 ± 7.2 |          | 0.764    | 57.0 ± 4.7    | 60.8 ± 1.0 |          | 0.111    |
| LVMI (g/m²)                    | 160.1 ± 28.05   | 160.8 ± 25.5 |          | 0.472    | 172.5 ± 31.8  | 177.8 ± 42.3 |          | 0.784    |
| BMI (kg/m²)                    | 25.7 ± 0.7      | 25.7 ± 1.4 |          | 0.579    | 25.7 ± 1.03   | 25.6 ± 1.7 |          | 0.867    |

BNP: Brain natriuretic peptid, EF: Ejection Fraction, Sd: Standard deviation, LVMI: Left ventricular mass index, BMI: Body mass index

Table 4: Characteristics of patients with HTRP (Grade I-II).

| Variables                      | HTRP Grade I (n=19) Mean ± Sd | HTRP Grade II (n=21) Mean ± Sd | P     |
|--------------------------------|--------------------------------|---------------------------------|-------|
| Age                            | 51.3 ± 5.4                     | 51.0 ± 5.9                       | 0.946 |
| Gender (male/female)           | 7/12                           | 10/11                           | 0.497 |
| Systolic blood pressure (mmHg) | 167.1 ± 13                     | 180.2 ± 12.7                     | 0.004 |
| Diastolic blood pressure (mmHg)| 98.4 ± 10.6                    | 105 ± 7.7                        | 0.049 |
| Urea (mg/dl)                   | 38.0 ± 9.2                     | 37.4 ± 8.9                       | 0.957 |
| Creatinine (mg/dl)             | 0.7 ± 0.1                      | 0.9 ± 0.2                        | 0.008 |
| Potassium (mEq/L)              | 4.3 ± 0.3                      | 4.4 ± 0.4                        | 0.946 |
| Sodium (mEq/L)                 | 142.9 ± 3.4                    | 141.3 ± 3.3                      | 0.203 |
| Serum BNP (mg/dl)              | 59.1 ± 19.7                    | 84.0 ± 33.7                      | 0.009 |
| Microalbuminuria (mg/24h)      | 14.05 ± 16.1                   | 46.9 ± 52.8                      | 0.013 |
| Microproteinuria (mg/24h)      | 147.8 ± 107.1                  | 257.4 ± 188.8                    | 0.027 |
| Creatinine clearance (ml/min)  | 97.8 ± 17.6                    | 88.5 ± 13.7                      | 0.057 |
| EF %                           | 60.3 ± 5.5                     | 59.4 ± 4.2                       | 0.226 |
| LVMI (g/m²)                    | 25.7 ± 0.9                     | 25.6 ± 1.4                       | 0.122 |

HTRP: Hypertensive Retinopathy, Sd: Standard deviation, BNP: Brain natriuretic peptid, EF: Ejection Fraction, LVMI: Left ventricular mass index, BMI: Body mass index
DISCUSSION

There are limited numbers of studies evaluating the relationship between serum BNP levels and RAS in the literature. RAS is a curable cause of renovascular hypertension. Untreated RAS is usually resulting in progressive loss of kidney functions and end-stage renal failure. Moreover 10-40% of end-stage renal failures develop from RAS (16,17). Due to the control effect of RAAS blocking agents on blood pressure, most of the patients with RAS remain asymptomatic until the development of end-stage renal failure. The gold standard diagnostic method of RAS is selective renal artery angiography (18,19). It is invasive and nefrotoxic. Additionally, kidney functional tests do not provide sufficient data for the diagnosis of RAS. Thus, biochemical markers are needed for early diagnosis of RAS, because early diagnosis may reduce the rate of mortality, morbidity, the need of dialysis and also the treatment costs of uncontrolled hypertension.

BNP is from natriuretic peptide group and plays an important role in renal physiology. The main source of circulating BNP is ventricular myocardial tissue; however, BNP synthesis and release have been shown in glomerular mesangial and epithelial cells (20). Left ventricular wall stress and volume load stimulate BNP secretion. Increased heart rate, endothelin I and especially AT II, can also induce serum BNP synthesis (21). BNP increases due to RAAS in patients with renovascular hypertension (10,11,22). Reasons that narrow renal artery lumen increase AT II levels by activating RAAS. Moreover, it has been reported that increased serum BNP levels decrease when AT I receptor blocker losartan was used (9). For patients who were suspected to have bilateral RAS, beta-blockers, ACE inhibitors or ARBs were not used. Therefore, patients have got no AT II inhibition. To the findings of comparisons between RAS patients and patients without stenosis revealed that RAS patients had significantly higher BNP levels. This significance occurred even in patients with stenosis less than 50%. In our study, the increased BNP levels in patients with RAS might have occurred due to stimulation of serum BNP release by increased AT II in the stenotic renal artery. We have detected a significant elevation in each case between the groups in terms of serum BNP. Although significant elevations between groups in terms of blood pressure were detected, there were no significant difference between patients with less than 50% stenosis and patients with more than 50% stenosis. Despite the lack of difference in blood pressure levels between the two groups, higher levels of serum BNP emerged as a remarkable finding. According to these findings, we think that serum BNP level evaluation in patients with uncontrolled hypertension may be helpful for early diagnosis of RAS. In their study, Muussalo et al. compared patients with renovascular hypertension to patients with moderate and to patients with severe hypertensive. They reported significantly higher levels of serum BNP and ANP in patients with RAS (23). Twelve patients with renal artery stenosis more than 50% were included in their study. They compared 37 patients with severe hypertension to 29 patients with moderate hypertension. In the study they reported 58% sensitivity and 90% specificity of serum BNP level in detecting RAS. However, they stated that they had few patients with RAS in the report. They found that sistolic and diastolic blood pressures were higher in RAS patient group. These results correlate with our findings. Although there was a difference between patients with severe hypertension and patients with moderate hypertension in terms of systolic and diastolic pressure levels, there was no significant difference between these groups in terms of BNP levels. Although there was no significant difference between critical stenosis group (Group 1b) and non-critical stenosis group (Group 1a) in terms of blood pressure levels, we found a significant difference in terms of BNP levels. We think that this allows us to exclude the impact of increased blood pressure on serum BNP level elevation due to ventricular wall stretch and hypertrophy. There are studies indicating the relationship between serum BNP levels and left ventricular mass in the literature (24). In our study, serum BNP levels and left ventricular mass index were not different among groups and they did not show any correlation between each other. The present study revealed that there was no impact of BNP elevation due to the stress of the ventricle. Silvia et al. found a decrease on serum BNP levels after renal revascularization in patients with RAS (25). In that study, it was reported that serum BNP levels were higher in 81% of the patients. They have achieved a decrease in BNP levels after revascularization with stents in these patients. In our study, we found higher levels of BNP in patients with more than 50% stenosis than patients with less than 50% stenosis. In their study, Silvia et al. accepted BNP levels more than 80 pg/ml as high and they reported that these patients benefited from revascularization (25). In the present study, 15% of the patients had non-critical stenosis and 85% of the patients had critical bilateral or unilateral stenosis, when patients with BNP levels more than 80 pg/ml were considered.

In an experimental study that evaluated RVD double-kidney one-clip model of left ventricular BNP levels, it was shown that BNP levels increased 6 hours after renal artery clamping, and remained high during 4 days after renal artery clamping (26). However, this model did not provide enough information about long-term BNP levels continue. The present study revealed that there was no impact of BNP elevation due to the stress of the ventricle. Silvia et al. found a decrease on serum BNP levels after renal revascularization in patients with RAS (25). In that study, it was reported that serum BNP levels were higher in 81% of the patients. They have achieved a decrease in BNP levels after revascularization with stents in these patients. In our study, we found higher levels of BNP in patients with more than 50% stenosis than patients with less than 50% stenosis. In their study, Silvia et al. accepted BNP levels more than 80 pg/ml as high and they reported that these patients benefited from revascularization (25). In the present study, 15% of the patients had non-critical stenosis and 85% of the patients had critical bilateral or unilateral stenosis, when patients with BNP levels more than 80 pg/ml were considered.

In an experimental study that evaluated RVD double-kidney one-clip model of left ventricular BNP levels, it was shown that BNP levels increased 6 hours after renal artery clamping, and remained high during 4 days after renal artery clamping (26). However, this model did not provide enough information about long-term BNP levels continue.
due to the short-term nature of the experiment. In another study, it was reported that increased BNP levels decreased to previous levels when double-kidney one-clip model was performed (22).

In the literature, there are conflicting studies regarding the effect of BNP on GFR. In their study conducted on 213 predialysis patients, Vickery et al. found a strong correlation between BNP and GFR (27). They reported that each 10 mL/min decrease of GFR resulted in 20.6% increase of BNP levels and 37.7% increase of NT-proBNP levels. However, Tagore et al. reported that N-terminal-proBNP levels were determined by left ventricular hypertrophy, hemoglobin and GFR while BNP levels remained unaffected (28). In their study conducted for investigating the roles of kidney, natriuretic peptide clearance (NPR-C) receptor and protease digestion in elimination of synthetic human BNP in rabbit plasma, Almirez et al. reported 1.5 times decrease in BNP elimination between the bilateral renal artery ligated group and control group. This shows that kidney is rich of NP-C receptor and protease (possibly NEP 24.11) and has a role in BNP metabolism (29). There are data suggesting that kidneys play a significant role in the removal of the BNP in humans. In a study conducted in 1993 by Richards et al. in which regional plasma levels of endogenous BNP in patients with cardiac disease were monitored, it was found a significant arteriovenous concentration gradient between femoral artery and renal vein which was a sign of the role of kidney on BNP removal (29). Schou et al. reported that both BNP and NT-proBNP were excreted by the kidneys (30). Khan et al. reported a strong correlation between BNP, NT-proBNP and GFR and an increase in serum BNP levels as chronic renal failure progresses (31). Tanemoto et al. published their study conducted to investigate the determinants of undiagnosed RAS on 202 Japanese patients with atherosclerosis risk. They used MRI in the diagnosis of RAS and considered atherosclerotic RAS as stenosis more than 50%. Patients with 0-50% stenosis were included in the control group. In their study, serum creatinine levels and creatinine clearance were identified as determinants of RAS (32). In our study, selective renal angiography, which is a gold standard for the detection of RAS, was used. The results showed that the patients with significant stenosis had elevated serum BNP levels and decreased creatinine clearance. This decrease in clearance was observed especially in patients with Group 1b (which is more than 50% stenosis), and both in patients with unilateral critical stenosis and bilateral critical stenosis.

In our study, we found a significantly higher level of microalbuminuria in patients with RAS. We found that this difference was especially originated from patients with more than 50% stenosis.

In the literature, there was not sufficient number of study investigating the relationship between serum BNP levels and RAS in humans. In this study, we aimed to evaluate whether or not there was a correlation between serum BNP levels and degree of RAS in patients who underwent renal arteriography due to RAS suspicion that resulted as RAS diagnosis. As a result, the findings of the present study suggest that serum BNP levels can be used as a determinant of RAS. Evaluation of BNP levels in patients with uncontrolled hypertension may lead the way for further studies.

We have focused on early detection of RAS using a non-invasive and available biochemical marker. Nowadays, the plasma BNP level has been used as a biological marker in the diagnosis and treatment of some diseases, especially for cardiovascular events (13). Measurement of BNP level may enable the early diagnosis and treatment of these diseases. Thus, it may allow to reduce the total cost of the management approaches (6,14). Recently, rapid BNP assay is now easily available to physicians in an office, clinic and emergency department. Findings of the present study presented that increased serum BNP levels were significantly associated with the severity of RAS determined by renal arteriography so BNP may be used as a predictive marker to detect presence of RAS in patients with resistant hypertension.
REFERENCES

1. Bloch MJ, Basile J. The diagnosis and management of renovascular disease: A primary care perspective. Part I. Making the diagnosis. J Clin Hypertens. 2003;5(3):210-218.

2. Bloch MJ, Basile J. Clinical insights into the diagnosis and management of renovascular disease. An evidence-based review. Minerva Med. 2004;95(5):357-373.

3. Zeller T. Percutaneous endovascular therapy of renal artery stenosis: Technical and clinical developments in the past decade. J Endovasc Ther. 2004;11(2):96-106.

4. Dubel GJ, Murphy TP. The role of percutaneous revascularization for renal artery stenosis. Vasc Med. 2008;13(2):141-156.

5. Bloch MJ: An evidence-based approach to diagnosing renovascular hypertension. Curr Cardiol Rep. 2001;3(6):477-484.

6. Safley DM, McCullough PA: The emerging role of brain natriuretic peptide in the management of acute and chronic heart failure in outpatients. Heart Fail Monit. 2003;4(1):13-20.

7. Miasel AS. B-type natriuretic peptide (BNP) levels: Diagnostic and therapeutic potential. Rev Cardiovasc Med. 2001;2:13-8.

8. Jensen KT, Carstens J, Ivarsen P, Pedersen EB. A new, fast and reliable radioimmunobassay of brain natriuretic peptide in human plasma. Reference values in healty subjects and in patients with different diseases. Scand J Clin Lab Invest. 1997;57:529-540.

9. Wiese S, Breyer T, Dragu A, Wakili R, Burkard T, Schmidt-Ullrich R. Kidney extract BNP in healty young men. Physiol. 2005;99:1676-1680.

10. Lai KN, Leung JC, Yandle TG, Fisher S, Nicholls MG. Gene expression and synthesis of natriuretic peptides by kultured human glomeruler cells. J Hypertens. 1999;17:575-583.

11. Nishimura M, Milsted A, Brosnihan KB, Ferrario CM. Tissue renin-angiotensin systems in renal hypertension. Hypertension. 1992;20:158-167.

12. Kurtz WK, Pfeifer M, Hochel K, Riegger GA, Kramer BK. Prevalence ofatherosclerotic renovascular disease. Am J Kidney Dis. 2001;38(6):1561-1569.

13. Safton RD, Textor SC. Renal-artery stenosis. N Engl J Med. 2001;344:431-442.

14. Wright JR, Shurrab AE, Cheung C, Waldek S, O’Donoghue DJ, Foley RN, Mamorta H, Kalra PA. A prospective study of determinants of renal functional outcome and in mortality atherosclerotic renovascular disease. Am J Kidney Dis. 2002;39:1153-1161.

15. Wright JR, Shurrab AE, Cheung C, Waldek S, O’Donoghue DJ, Foley RN, Mamorta H, Kalra PA. A prospective study of determinants of renal functional outcome and in mortality atherosclerotic renovvascular disease. Am J Kidney Dis. 2002;39:1153-1161.

16. van Ampting JM, Penne EL, Beek FJ, Koomans HA, Boer WH, Beutler JJ. Prevalence ofatherosclerotic renal artery stenosis in patients starting dialysis. Nephrol Dial Transplant. 2003;18(6):1147-1151.

17. van Ampting JM, Penne EL, Beek FJ, Koomans HA, Boer WH, Beutler JJ. Prevalence ofatherosclerotic renal artery stenosis in patients starting dialysis. Nephrol Dial Transplant. 2003;18(6):1147-1151.

18. Uygun İlikhan S and Bilici M
31. Khan IA, Fink J, Nass C, Chen H, Christenson R, deFilippi CR. N-terminal pro-B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J Cardiol. 2006;97:1530-1534.

32. Tanemoto M, Saitoh H, Satoh F, Satoh H, Abe T, Ito S. Predictors of undiagnosed renal artery stenosis among Japanese patients with risk factors of atherosclerosis. Hypertens Res. 2005;28:237-242.

33. Park S, Jung JH, Seo HS, Ko YG, Choi D, Jang Y, Chung N, Cho SY, Shim WH. The prevalence and clinical predictors of atherosclerotic renal artery stenosis in patients undergoing coronary angiography. Heart Vessels. 2004;19:275-279.

34. Bianchi S, Bigazzi R, Campese VM. Microalbuminuria in essential hypertension. J Nephrol. 1997;10(4): 216-219.

35. Asakawa H, Fukui T, Tokunaga K, Kawakami F. Plasma brain natriuretic peptide levels in normotensive Type 2 diabetic patients without cardiac disease and macroalbuminuria. J Diabetes Complications. 2002;16(3):209-213.

36. Igarashi M, Jimbu Y, Hirata A, Tominaga M. Characterization of plasma brain natriuretic peptide level in patients with type 2 diabetes. Endocr J. 2005;52(3): 353-362.
